MAX BioPharma, Inc. and Revilico, Inc. announced their collaboration in studying the mechanisms of action, performing lead optimization, and identifying the molecular targets of MAX BioPharma’s oxysterol-based drug candidates using a state-of-the-art, AI-enabled, end-to-end drug discovery platform developed by Revilico.

View the original press release >